Source: Virtual Congress 2020 – Tuberculosis: part 2
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Fujita (Kyoto, Japan), Y. Yamamoto (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan). Preliminary evaluation of serial interferon-gamma releasing assay testing in NSCLC patients treated with immune checkpoint inhibitors. 5298

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of serial interferon-gamma release assay testing in lung cancer patients treated with immune checkpoint inhibitors Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021 Serial interferon-gamma release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 Predictive biomarker of immune checkpoint inhibitors efficacy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 An evaluation of the use of a negative interferon gamma release assay for tuberculosis screening before TNF antagonist therapy Source: Eur Respir J 2014; 44: 1369-1372 Year: 2014 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 Use of immune cell function assay in immune surveillance of lung transplant recipients: Correlations with clinical outcome and other immune assays Source: Annual Congress 2012 - Optimising outcomes after lung transplantation Year: 2012 The clinical benefits of immune checkpoint inhibitors for thymic carcinomas Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Comparison of whole-blood interferon-gamma release assay and tuberculin skin test results for the prediction of active tuberculosis disease in HIV-infected individuals Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Diagnostic performance of the interferon gamma release assay in elderly patients and clinical factors to support the diagnosis of active tuberculosis Source: Annual Congress 2012 - Tuberculosis and immunologic assays Year: 2012 Clinical evaluation of interferon-gamma release assay (IGRA) in patients with nontuberculous mycobacterial disease Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012 Serial interferon-gamma release assay in children with tuberculosis infection Source: Annual Congress 2010 - Tuberculosis in children Year: 2010 Sequential analysis of interferon-γ release assay results in active tuberculosis patients Source: Annual Congress 2009 - From bench to bedside: diagnosis of tuberculosis Year: 2009 Clinical evaluation of two interferon-gamma release assay tests for immunocompromised patients Source: Annual Congress 2010 - Interferon-gamma releases assays (IGRAs) for the diagnosis of tuberculosis: what is the role? Year: 2010 The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 The efficacy of immune checkpoint inhibitors in thoracic malignancies Source: Eur Respir Rev, 30 (162) 200387; 10.1183/16000617.0387-2020 Year: 2021 CellCollector®: A novel method for the isolation of circulating tumor cells (CTC) in vivo and ex vivo in lung cancer patients during therapy Source: International Congress 2016 – Lung cancer and immune cells: friends or foes? Year: 2016 Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs Source: Eur Respir J 2009; 34: 702 Year: 2009 Support of ex vivo IFN-gamma release assays in the diagnosis of tuberculosis infection in HIV/AIDS patients Source: Annual Congress 2008 - Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease Year: 2008 Immune checkpoint inhibitors in lung cancer Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016